Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $49.30 | Total: $246.50 |
| 1 | 10 | $41.76 | Total: $417.60 |
| 1 | 25 | $35.38 | Total: $884.50 |
| 1 | 50 | $30.16 | Total: $1,508.00 |
| 1 | 100 | $26.10 | Total: $2,610.00 |
Overview
B2 (Linazolamide intermediate B impurity 2) promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease
Chemical Properties
| Molecular Formula | C20H17ClN4O3 |
| Molecular Weight | 396.83 |
| CAS Numbers | 115687-05-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [O-][N+](=O)c1ccc(N2CCN(CC2)C(=O)c2ccc(Cl)cc2)c2cccnc12 |
Storage and Handling
0C Short Term, -20C Long Term
References
Bodner et al [2006] Pharmacological promotion of inclusion formation a therapeutic approach for Huntington's and Parksinson's diseases. Proc.Natl.Acad.Sci.USA 103 4246